Cancer stem cells and their interaction with the tumor microenvironment in neuroblastoma

Cancers

Volumn 8, Issue 1, 2015, Pages

  Garner, Evan F ^a   Beierle, Elizabeth A ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Cancer stem cell; Cancer associated fibroblasts; Hypoxia; Neuroblastoma

Indexed keywords

BEVACIZUMAB; CHEMOKINE; CYTOKINE; LENALIDOMIDE; PROTEASOME INHIBITOR; RAPAMYCIN; RETINOIC ACID;

CANCER STEM CELL; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CELL RENEWAL; EVENT FREE SURVIVAL; EXTRACELLULAR MATRIX; FIBROBLAST; GENETIC HETEROGENEITY; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; MACROPHAGE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84953334466     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers8010005     Document Type: Review

References (96)

1. Ishola, T.A.; Chung, D.H. Neuroblastoma. Surg. Oncol. 2007, 16, 149-156. [CrossRef] [PubMed]
2. Matthay, K.K.; Villablanca, J.G.; Seeger, R.C.; Stram, D.O.; Harris, R.E.; Ramsay, N.K.; Swift, P.; Shimada, H.; Black, C.T.; Brodeur, G.M.; et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's cancer group. N. Engl. J. Med. 1999, 341, 1165-1173. [CrossRef] [PubMed]
3. Cohn, S.L.; Pearson, A.D.; London, W.B.; Monclair, T.; Ambros, P.F.; Brodeur, G.M.; Faldum, A.; Hero, B.; Iehara, T.; Machin, D.; et al. The international neuroblastoma risk group (INRG) classification system: An INRG task force report. J. Clin. Oncol. 2009, 27, 289-297. [CrossRef] [PubMed]
4. DuBois, S.G.; Kalika, Y.; Lukens, J.N.; Brodeur, G.M.; Seeger, R.C.; Atkinson, J.B.; Haase, G.M.; Black, C.T.; Perez, C.; Shimada, H.; et al. Metastatic sites in stage IV and IVs neuroblastoma correlate with age, tumor biology, and survival. J. Pediatr. Hematol. Oncol. 1999, 21, 181-189. [CrossRef] [PubMed]
5. Navid, F.; Armstrong, M.; Barfield, R.C. Immune therapies for neuroblastoma. Cancer Biol. Ther. 2009, 8, 874-882. [CrossRef] [PubMed]
6. Maris, J.M.; Hogarty, M.D.; Bagatell, R.; Cohn, S.L. Neuroblastoma. Lancet 2007, 369, 2106-2120. [CrossRef]
7. Özdemir, B.C.; Pentcheva-Hoang, T.; Carstens, J.L.; Zheng, X.; Wu, C.C.; Simpson, T.R.; Laklai, H.; Sugimoto, H.; Kahlert, C.; Novitskiy, S.V.; et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014, 25, 719-734. [CrossRef] [PubMed]
8. Rhim, A.D.; Oberstein, P.E.; Thomas, D.H.; Mirek, E.T.; Palermo, C.F.; Sastra, S.A.; Dekleva, E.N.; Saunders, T.; Becerra, C.P.; Tattersall, I.W.; et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014, 25, 735-747. [CrossRef] [PubMed]
9. Chen, F.; Zhuang, X.; Lin, L.; Yu, P.; Wang, Y.; Shi, Y.; Hu, G.; Sun, Y. New horizons in tumor microenvironment biology: Challenges and opportunities. BMC Med. 2015, 13, 45. [CrossRef] [PubMed]
10. Sounni, N.E.; Noel, A. Targeting the tumor microenvironment for cancer therapy. Clin. Chem. 2013, 59, 85-93. [CrossRef] [PubMed]
11. Hanahan, D.; Coussens, L.M. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21, 309-322. [CrossRef] [PubMed]
12. Zhi, Y.; Duan, Y.; Zhou, X.; Yin, X.; Guan, G.; Zhang, H.; Dong, Q.; Yang, K. NF-κB signaling pathway confers neuroblastoma cells migration and invasion ability via the regulation of CXCR4. Med. Sci. Monit. 2014, 20, 2746-2752. [PubMed]
13. Clarke, M.F.; Dick, J.E.; Dirks, P.B.; Eaves, C.J.; Jamieson, C.H.; Jones, D.L.; Visvader, J.; Weissman, I.L.; Wahl, G.M. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006, 66, 9339-9344. [CrossRef] [PubMed]
14. Chen, K.; Huang, Y.H.; Chen, J.L. Understanding and targeting cancer stem cells: Therapeutic implications and challenges. Acta. Pharmacol. Sin. 2013, 34, 732-740. [CrossRef] [PubMed]
15. Alisi, A.; Cho, W.C.; Locatelli, F.; Fruci, D. Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. Int. J. Mol. Sci. 2013, 14, 24706-24725. [CrossRef] [PubMed]
16. Abdullah, L.N.; Chow, E.K. Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med. 2013, 2, 3. [CrossRef] [PubMed]
17. Vlashi, E.; McBride, W.H.; Pajonk, F. Radiation responses of cancer stem cells. J. Cell Biochem. 2009, 108, 339-342. [CrossRef] [PubMed]
18. Buhagiar, A.; Ayers, D. Chemoresistance, cancer stem cells, and miRNA influences: The case for neuroblastoma. Anal. Cell Pathol. 2015, 2015, 150634. [CrossRef] [PubMed]
19. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5, 275-284. [CrossRef] [PubMed]
20. Hansford, L.M.; McKee, A.E.; Zhang, L.; George, R.E.; Gerstle, J.T.; Thorner, P.S.; Smith, K.M.; Look, A.T.; Yeger, H.; Miller, F.D.; et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res. 2007, 67, 11234-11243. [CrossRef] [PubMed]
21. Ross, R.A.; Spengler, B.A.; Domènech, C.; Porubcin, M.; Rettig, W.J.; Biedler, J.L. Human neuroblastoma I-type cells are malignant neural crest stem cells. Cell Growth Differ. 1995, 6, 449-456. [PubMed]
22. Walton, J.D.; Kattan, D.R.; Thomas, S.K.; Spengler, B.A.; Guo, H.F.; Biedler, J.L.; Cheung, N.K.; Ross, R.A. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 2004, 6, 838-845. [CrossRef] [PubMed]
23. Ross, R.A.; Spengler, B.A. Human neuroblastoma stem cells. Semin. Cancer Biol. 2007, 17, 241-247. [CrossRef] [PubMed]
24. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367, 645-648. [CrossRef] [PubMed]
25. Hirschmann-Jax, C.; Foster, A.E.;Wulf, G.G.; Nuchtern, J.G.; Jax, T.W.; Gobel, U.; Goodell, M.A.; Brenner, M.K. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004, 101, 14228-14233. [CrossRef] [PubMed]
26. Islam, M.O.; Kanemura, Y.; Tajria, J.; Mori, H.; Kobayashi, S.; Hara, M.; Yamasaki, M.; Okano, H.; Miyake, J. Functional expression of ABCG2 transporter in human neural stem/progenitor cells. Neurosci. Res. 2005, 52, 75-82. [CrossRef] [PubMed]
27. Neradil, J.; Veselska, R. Nestin as a marker of cancer stem cells. Cancer Sci. 2015, 106, 803-811. [CrossRef] [PubMed]
28. Xing, L.L.; Sha, Y.L.; Wu, Y.M.; Hu, J.M.; Zhang, M.; Lv, F. Preliminary analysis of stem cell-like cells in human neuroblastoma. World J. Pediatr. 2015, 11, 54-60. [CrossRef] [PubMed]
29. Mahller, Y.Y.; Williams, J.P.; Baird, W.H.; Mitton, B.; Grossheim, J.; Saeki, Y.; Cancelas, J.A.; Ratner, N.; Cripe, T.P. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 2009, 4, e4235. [CrossRef] [PubMed]
30. Yin, A.H.; Miraglia, S.; Zanjani, E.D.; Almeida-Porada, G.; Ogawa, M.; Leary, A.G.; Olweus, J.; Kearney, J.; Buck, D.W. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90, 5002-5012. [PubMed]
31. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature 2004, 432, 396-401. [CrossRef] [PubMed]
32. Kamijo, T. Role of stemness-related molecules in neuroblastoma. Pediatr. Res. 2012, 71, 511-515. [CrossRef] [PubMed]
33. Takenobu, H.; Shimozato, O.; Nakamura, T.; Ochiai, H.; Yamaguchi, Y.; Ohira, M.; Nakagawara, A.; Kamijo, T. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011, 30, 97-105. [CrossRef] [PubMed]
34. Cournoyer, S.; Nyalendo, C.; Addioui, A.; Belounis, A.; Beaunoyer, M.; Aumont, A.; Teira, P.; Duval, M.; Fernandes, K.; Fetni, R.; et al. Genotype analysis of tumor-initiating cells expressing CD133 in neuroblastoma. Genes Chromosom. Cancer 2012, 51, 792-804. [CrossRef] [PubMed]
35. Friedman, G.K.; Gillespie, G.Y. Cancer stem cells and pediatric solid tumors. Cancers 2011, 3, 298-318. [CrossRef] [PubMed]
36. Sartelet, H.; Imbriglio, T.; Nyalendo, C.; Haddad, E.; Annabi, B.; Duval, M.; Fetni, R.; Victor, K.; Alexendrov, L.; Sinnett, D.; et al. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopathology 2012, 60, 1144-1155. [CrossRef] [PubMed]
37. Hadnagy, A.; Gaboury, L.; Beaulieu, R.; Balicki, D. SP analysis may be used to identify cancer stem cell populations. Exp. Cell Res. 2006, 312, 3701-3710. [CrossRef] [PubMed]
38. Komuro, H.; Saihara, R.; Shinya, M.; Takita, J.; Kaneko, S.; Kaneko, M.; Hayashi, Y. Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. J. Pediatr. Surg. 2007, 42, 2040-2045. [CrossRef] [PubMed]
39. Newton, T.C.; Wolcott, K.; Roberts, S.S. Comparison of the side populations in pretreatment and postrelapse neuroblastoma cell lines. Transl. Oncol. 2010, 3, 246-251. [CrossRef] [PubMed]
40. Hsu, D.M.; Agarwal, S.; Benham, A.; Coarfa, C.; Trahan, D.N.; Chen, Z.; Stowers, P.N.; Courtney, A.N.; Lakoma, A.; Barbieri, E.; et al. G-csf receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 2013, 73, 4134-4146. [CrossRef] [PubMed]
41. Marcato, P.; Dean, C.A.; Giacomantonio, C.A.; Lee, P.W. Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011, 10, 1378-1384. [CrossRef] [PubMed]
42. Hartomo, T.B.; Van Huyen Pham, T.; Yamamoto, N.; Hirase, S.; Hasegawa, D.; Kosaka, Y.; Matsuo, M.; Hayakawa, A.; Takeshima, Y.; Iijima, K.; et al. Involvement of aldehyde dehydrogenase 1A2 in the regulation of cancer stem cell properties in neuroblastoma. Int. J. Oncol. 2015, 46, 1089-1098. [CrossRef] [PubMed]
43. Cantilena, S.; Pastorino, F.; Pezzolo, A.; Chayka, O.; Pistoia, V.; Ponzoni, M.; Sala, A. Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas. Oncotarget 2011, 2, 976-983. [CrossRef] [PubMed]
44. Fuchs, E.; Tumbar, T.; Guasch, G. Socializing with the neighbors: Stem cells and their niche. Cell 2004, 116, 769-778. [CrossRef]
45. Ye, J.;Wu, D.;Wu, P.; Chen, Z.; Huang, J. The cancer stem cell niche: Cross talk between cancer stem cells and their microenvironment. Tumour. Biol. 2014, 35, 3945-3951. [CrossRef] [PubMed]
46. Pistollato, F.; Abbadi, S.; Rampazzo, E.; Persano, L.; Della Puppa, A.; Frasson, C.; Sarto, E.; Scienza, R.; D'avella, D.; Basso, G. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 2010, 28, 851-862. [CrossRef] [PubMed]
47. Shigdar, S.; Li, Y.; Bhattacharya, S.; O'Connor, M.; Pu, C.; Lin, J.;Wang, T.; Xiang, D.; Kong, L.;Wei, M.Q.; et al. Inflammation and cancer stem cells. Cancer Lett. 2014, 345, 271-278. [CrossRef] [PubMed]
48. Hjelmeland, A.B.; Wu, Q.; Heddleston, J.M.; Choudhary, G.S.; MacSwords, J.; Lathia, J.D.; McLendon, R.; Lindner, D.; Sloan, A.; Rich, J.N. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011, 18, 829-840. [CrossRef] [PubMed]
49. Lu, P.;Weaver, V.M.;Werb, Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell Biol. 2012, 196, 395-406. [CrossRef] [PubMed]
50. Crowder, S.W.; Balikov, D.A.; Hwang, Y.S.; Sung, H.J. Cancer stem cells under hypoxia as a chemoresistance factor in breast and brain. Curr. Pathobiol. Rep. 2014, 2, 33-40. [CrossRef] [PubMed]
51. Lin, Q.; Yun, Z. Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics. Cancer Biol. Ther. 2010, 9, 949-956. [CrossRef] [PubMed]
52. Das, B.; Tsuchida, R.; Malkin, D.; Koren, G.; Baruchel, S.; Yeger, H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008, 26, 1818-1830. [CrossRef] [PubMed]
53. Jögi, A.; Øra, I.; Nilsson, H.; Lindeheim, A.; Makino, Y.; Poellinger, L.; Axelson, H.; Påhlman, S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc. Natl. Acad. Sci. USA 2002, 99, 7021-7026. [CrossRef] [PubMed]
54. Holmquist-Mengelbier, L.; Fredlund, E.; Löfstedt, T.; Noguera, R.; Navarro, S.; Nilsson, H.; Pietras, A.; Vallon-Christersson, J.; Borg, A.; Gradin, K.; et al. Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell 2006, 10, 413-423. [CrossRef] [PubMed]
55. Pietras, A.; Hansford, L.M.; Johnsson, A.S.; Bridges, E.; Sjölund, J.; Gisselsson, D.; Rehn, M.; Beckman, S.; Noguera, R.; Navarro, S.; et al. HIF-2α maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc. Natl. Acad. Sci. USA 2009, 106, 16805-16810. [CrossRef] [PubMed]
56. Covello, K.L.; Kehler, J.; Yu, H.; Gordan, J.D.; Arsham, A.M.; Hu, C.J.; Labosky, P.A.; Simon, M.C.; Keith, B. HIF-2α regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006, 20, 557-570. [CrossRef] [PubMed]
57. Martin, C.M.; Ferdous, A.; Gallardo, T.; Humphries, C.; Sadek, H.; Caprioli, A.; Garcia, J.A.; Szweda, L.I.; Garry, M.G.; Garry, D.J. Hypoxia-inducible factor-2α transactivates ABCG2 and promotes cytoprotection in cardiac side population cells. Circ. Res. 2008, 102, 1075-1081. [CrossRef] [PubMed]
58. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T.L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.; Finklestein, D.; Allen, M.; et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11, 69-82. [CrossRef] [PubMed]
59. Pietras, A.; Gisselsson, D.; Ora, I.; Noguera, R.; Beckman, S.; Navarro, S.; Påhlman, S. High levels of HIF-2α highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. J. Pathol. 2008, 214, 482-488. [CrossRef] [PubMed]
60. Zeine, R.; Salwen, H.R.; Peddinti, R.; Tian, Y.; Guerrero, L.; Yang, Q.; Chlenski, A.; Cohn, S.L. Presence of cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors. Mod. Pathol. 2009, 22, 950-958. [CrossRef] [PubMed]
61. Lacina, L.; Plzak, J.; Kodet, O.; Szabo, P.; Chovanec, M.; Dvorankova, B.; Smetana, K. Cancer microenvironment: What can we learn from the stem cell niche. Int. J. Mol. Sci. 2015, 16, 24094-24110. [CrossRef] [PubMed]
62. Xing, F.; Saidou, J.;Watabe, K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front. Biosci. 2010, 15, 169-179. [CrossRef]
63. Jodele, S.; Chantrain, C.F.; Blavier, L.; Lutzko, C.; Crooks, G.M.; Shimada, H.; Coussens, L.M.; Declerck, Y.A. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res. 2005, 65, 3200-3208. [PubMed]
64. Brundula, V.; Rewcastle, N.B.; Metz, L.M.; Bernard, C.C.; Yong, V.W. Targeting leukocyte mmps and transmigration: Minocycline as a potential therapy for multiple sclerosis. Brain 2002, 125, 1297-1308. [CrossRef] [PubMed]
65. Chantrain, C.F.; Shimada, H.; Jodele, S.; Groshen, S.; Ye, W.; Shalinsky, D.R.; Werb, Z.; Coussens, L.M.; DeClerck, Y.A. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004, 64, 1675-1686. [CrossRef] [PubMed]
66. Sugiura, Y.; Shimada, H.; Seeger, R.C.; Laug, W.E.; DeClerck, Y.A. Matrix metalloproteinases-2 and-9 are expressed in human neuroblastoma: Contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 1998, 58, 2209-2216. [PubMed]
67. Zhang, H.; Qi, M.; Li, S.; Qi, T.; Mei, H.; Huang, K.; Zheng, L.; Tong, Q. Microrna-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol. Cancer Ther. 2012, 11, 1454-1466. [CrossRef] [PubMed]
68. Tan, T.T.; Coussens, L.M. Humoral immunity, inflammation and cancer. Curr. Opin. Immunol. 2007, 19, 209-216. [CrossRef] [PubMed]
69. Asgharzadeh, S.; Salo, J.A.; Ji, L.; Oberthuer, A.; Fischer, M.; Berthold, F.; Hadjidaniel, M.; Liu, C.W.; Metelitsa, L.S.; Pique-Regi, R.; et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J. Clin. Oncol. 2012, 30, 3525-3532. [CrossRef] [PubMed]
70. Carlson, L.M.; de Geer, A.; Sveinbjørnsson, B.; Orrego, A.; Martinsson, T.; Kogner, P.; Levitskaya, J. The microenvironment of human neuroblastoma supports the activation of tumor-associated t lymphocytes. Oncoimmunology. 2013, 2, e23618. [CrossRef] [PubMed]
71. Pistoia, V.; Morandi, F.; Bianchi, G.; Pezzolo, A.; Prigione, I.; Raffaghello, L. Immunosuppressive microenvironment in neuroblastoma. Front. Oncol. 2013, 3, 167. [CrossRef] [PubMed]
72. Zumsteg, A.; Christofori, G. Corrupt policemen: Inflammatory cells promote tumor angiogenesis. Curr. Opin. Oncol. 2009, 21, 60-70. [CrossRef] [PubMed]
73. Song, L.; Asgharzadeh, S.; Salo, J.; Engell, K.; Wu, H.W.; Sposto, R.; Ara, T.; Silverman, A.M.; de Clerck, Y.A.; Seeger, R.C.; et al. Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Investig. 2009, 119, 1524-1536. [CrossRef] [PubMed]
74. Bottino, C.; Dondero, A.; Bellora, F.; Moretta, L.; Locatelli, F.; Pistoia, V.; Moretta, A.; Castriconi, R. Natural killer cells and neuroblastoma: Tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front. Immunol. 2014, 5, 56. [CrossRef] [PubMed]
75. Sivori, S.; Parolini, S.; Marcenaro, E.; Castriconi, R.; Pende, D.; Millo, R.; Moretta, A. Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J. Neuroimmunol. 2000, 107, 220-225. [CrossRef]
76. Castriconi, R.; Dondero, A.; Cilli, M.; Ognio, E.; Pezzolo, A.; De Giovanni, B.; Gambini, C.; Pistoia, V.; Moretta, L.; Moretta, A.; et al. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/SCID mice. Cancer Immunol. Immunother. 2007, 56, 1733-1742. [CrossRef] [PubMed]
77. Castriconi, R.; Dondero, A.; Corrias, M.V.; Lanino, E.; Pende, D.; Moretta, L.; Bottino, C.; Moretta, A. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: Critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 2004, 64, 9180-9184. [CrossRef] [PubMed]
78. Metelitsa, L.S.;Wu, H.W.;Wang, H.; Yang, Y.;Warsi, Z.; Asgharzadeh, S.; Groshen, S.;Wilson, S.B.; Seeger, R.C. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 2004, 199, 1213-1221. [CrossRef] [PubMed]
79. Ljunggren, H.G.; Malmberg, K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 2007, 7, 329-339. [CrossRef] [PubMed]
80. Heczey, A.; Liu, D.; Tian, G.; Courtney, A.N.;Wei, J.; Marinova, E.; Gao, X.; Guo, L.; Yvon, E.; Hicks, J.; et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 2014, 124, 2824-2833. [CrossRef] [PubMed]
81. Xu, Y.; Sun, J.; Sheard, M.A.; Tran, H.C.;Wan, Z.; Liu, W.Y.; Asgharzadeh, S.; Sposto, R.;Wu, H.W.; Seeger, R.C. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. Cancer Immunol. Immunother. 2013, 62, 1637-1648. [CrossRef] [PubMed]
82. Santilli, G.; Piotrowska, I.; Cantilena, S.; Chayka, O.; D'Alicarnasso, M.; Morgenstern, D.A.; Himoudi, N.; Pearson, K.; Anderson, J.; Thrasher, A.J.; et al. Polyphenon [corrected] e enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. Clin. Cancer Res. 2013, 19, 1116-1125. [CrossRef] [PubMed]
83. Kucia, M.; Reca, R.; Miekus, K.; Wanzeck, J.; Wojakowski, W.; Janowska-Wieczorek, A.; Ratajczak, J.; Ratajczak, M.Z. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23, 879-894. [CrossRef] [PubMed]
84. Orimo, A.; Gupta, P.B.; Sgroi, D.C.; Arenzana-Seisdedos, F.; Delaunay, T.; Naeem, R.; Carey, V.J.; Richardson, A.L.; Weinberg, R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121, 335-348. [CrossRef] [PubMed]
85. Geminder, H.; Sagi-Assif, O.; Goldberg, L.; Meshel, T.; Rechavi, G.; Witz, I.P.; Ben-Baruch, A. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J. Immunol. 2001, 167, 4747-4757. [CrossRef] [PubMed]
86. Russell, H.V.; Hicks, J.; Okcu, M.F.; Nuchtern, J.G. CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J. Pediatr. Surg. 2004, 39, 1506-1511. [CrossRef] [PubMed]
87. Zhang, L.; Yeger, H.; Das, B.; Irwin, M.S.; Baruchel, S. Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma. Neoplasia 2007, 9, 36-46. [CrossRef] [PubMed]
88. Louvi, A.; Artavanis-Tsakonas, S. Notch signaling in vertebrate neural development. Nat. Rev. Neurosci. 2006, 7, 93-102. [CrossRef] [PubMed]
89. Bolós, V.; Blanco, M.; Medina, V.; Aparicio, G.; Díaz-Prado, S.; Grande, E. Notch signalling in cancer stem cells. Clin. Transl. Oncol. 2009, 11, 11-19. [CrossRef] [PubMed]
90. Ferrari-Toninelli, G.; Bonini, S.A.; Uberti, D.; Buizza, L.; Bettinsoli, P.; Poliani, P.L.; Facchetti, F.; Memo, M. Targeting notch pathway induces growth inhibition and differentiation of neuroblastoma cells. Neuro. Oncol. 2010, 12, 1231-1243. [PubMed]
91. Xu, L.; Wang, X.; Wan, J.; Li, T.; Gong, X.; Zhang, K.; Yi, L.; Xiang, Z.; Xu, M.; Cui, H. Sonic hedgehog pathway is essential for neuroblastoma cell proliferation and tumor growth. Mol. Cell Biochem. 2012, 364, 235-241. [CrossRef] [PubMed]
92. Vangipuram, S.D.; Buck, S.A.; Lyman, W.D. Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line. Tumour. Biol. 2012, 33, 2173-2183. [CrossRef] [PubMed]
93. Smith, K.M.; Datti, A.; Fujitani, M.; Grinshtein, N.; Zhang, L.; Morozova, O.; Blakely, K.M.; Rotenberg, S.A.; Hansford, L.M.; Miller, F.D.; et al. Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol. Med. 2010, 2, 371-384. [CrossRef] [PubMed]
94. Hämmerle, B.; Yañez, Y.; Palanca, S.; Cañete, A.; Burks, D.J.; Castel, V.; Font de Mora, J. Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor. PLoS ONE 2013, 8, e76761. [CrossRef] [PubMed]
95. Segerström, L.; Fuchs, D.; Bäckman, U.; Holmquist, K.; Christofferson, R.; Azarbayjani, F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr. Res. 2006, 60, 576-581. [CrossRef] [PubMed]
96. Yu, A.L.; Gilman, A.L.; Ozkaynak, M.F.; London, W.B.; Kreissman, S.G.; Chen, H.X.; Smith, M.; Anderson, B.; Villablanca, J.G.; Matthay, K.K.; et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 2010, 363, 1324-1334. [CrossRef] [PubMed]